The Michael J. Fox Foundation for Parkinson’s Research seeks to support research that will develop new or improve upon existing biomarker tools for neuroinflammation/peripheral inflammation in Parkinson’s disease (PD). The specific goals of this initiative are to:
- facilitate the development of biomarker measures that can be utilized for novel target validation,
- assess pathological progression or phenoconversion, or
- identify inflammation paradigms unique to PD.
Proposed biomarkers should facilitate objective decisions to validate a particular target or target efficacy marker (downstream readouts of successful target modification), improve the ability to enrich subject populations in clinical trials and/or determine whether experimental treatments are modifying the course of the disease, its symptoms, or its progression.
Funding & Duration
1-2 year grants are available, for up to USD $300,000 (approx AUD $393,600)
Eligibility
Applications are encouraged from: U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held; and U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
Post-doctoral fellows are not eligible to apply as principal investigators to this program.
Submission Requirements & Due Dates
- 31 May 2017 – Letter of Intent (LOI) submitted directly to Sponsor
- Please send a copy of your LOI to rbinternational@adelaide.edu.au
- 23 June – full applications (by invitation only) submitted for internal review.
- Submit an Application to Research Services for Review